GORE VIABIL Biliary Endoprosthesis
Device Devices
PDI 00733132615414
General payments
$85,758
Research payments
$0
Through program year 2025, $85,758 in general payments and $0 in research payments were reported against GORE VIABIL Biliary Endoprosthesis (Devices).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $576 | 17 |
| 2024 | General | $45,616 | 72 |
| 2023 | General | $8,563 | 34 |
| 2022 | General | $23,145 | 34 |
| 2021 | General | $7,858 | 18 |
Breakdown
The top 5 of 16 recipients; each share is of general payments naming this product in 2025.
The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 7 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
175 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.